GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Net Change in Cash : ₦7,227 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

GlaxoSmithKline Consumer Nigeria's Net Change in Cash for the three months ended in Jun. 2023 was ₦0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was ₦7,227 Mil.

GlaxoSmithKline Consumer Nigeria Net Change in Cash Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Net Change in Cash Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

Get a 7-Day Free Trial

-9,920.71

321.87

9,174.77

-139.01

7,229.45

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Net Change in Cash	Get a 7-Day Free Trial															-1,457.33	1,588.30	5,318.80	1,777.62	-

GlaxoSmithKline Consumer Nigeria Net Change in Cash Calculation

GlaxoSmithKline Consumer Nigeria's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	7107.525	+	453.64	+	-333.77	+	2.058
	=	7,229

GlaxoSmithKline Consumer Nigeria's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦7,227 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Consumer Nigeria Net Change in Cash Related Terms
Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Net Change in Cash

Comparable Companies

NSA:UBNP NSA:CUSTODIAN NSA:AIIC NSA:FBP NSA:STERLINGNG NSA:MBAS NSA:WEMA NSA:FCMB NSA:JUBR NSA:NSLTECH LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines